Core Viewpoint - CollPlant has been granted U.S. Patent No. 12,186,449 for its photocurable dermal filler product, which is based on modified recombinant human collagen and hyaluronic acid, expiring on May 2, 2039 [1][2]. Dermal Filler Program - CollPlant has an exclusive licensing agreement with AbbVie for the use of its rhCollagen technology in dermal and soft tissue fillers [3]. - AbbVie is currently reviewing interim results from clinical trials initiated in 2023, with next steps to be determined after complete assessment [4]. Financial Developments - CollPlant received a contingent payment of $2 million from AbbVie related to its rhCollagen technology as per their agreement [4]. - The company has initiated a cost-cutting plan, reducing its workforce by approximately 20%, which is expected to sustain business activities until at least Q2 2026 [5]. Future Focus - In 2025, CollPlant plans to advance its product candidate pipeline, including the development of a regenerative breast implant towards clinical phases [6]. Company Overview - CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting of tissues and organs, with products based on its proprietary rhCollagen technology [7].
CollPlant Biotechnologies Provides a Corporate Update